ClinicalTrials.gg

Program

AB-101

Also written as “zabalafin”.

Its studies are mostly in Hepatitis B, Chronic · Lymphoma, Non-Hodgkin · Lupus Nephritis · Hodgkin Disease · Dermatitis, Atopic, led by 5 companies.

Furthest: phase 2, since Dec 4, 20206 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Artiva Biotherapeutics21 open or runningphase 2since Dec 4, 2020Dec 4, 2020Aug 2027phase 1 · NCT06265220
Affimed10 open or runningphase 2since May 19, 2023May 19, 2023none ahead
Alphyn Biologics11 open or runningphase 2since Feb 27, 2025Feb 27, 2025none ahead
Applied Biology10 open or runningearly phase 1since Jul 8, 2018Jul 8, 2018none ahead
Arbutus Biopharma10 open or runningphase 1since Jul 14, 2023Jul 14, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2018First study: early phase 1 study in Sexual Dysfunction, PhysiologicalNew to Applied BiologyApplied Biology · NCT03592121 · 3 enrolled · United States
  2. Dec 4, 2020Artiva Biotherapeutics's first study: phase 2 study in Lymphoma, Non-HodgkinNew to Artiva BiotherapeuticsArtiva Biotherapeutics · NCT04673617 · 45 enrolled · United States
  3. May 19, 2023Affimed's first study: phase 2 study in RecurrenceNew to AffimedAffimed · NCT05883449 · 25 enrolled · United States
  4. Jul 14, 2023Arbutus Biopharma's first study: phase 1 study in Hepatitis B, ChronicNew to Arbutus BiopharmaArbutus Biopharma · NCT05960240 · 128 enrolled · Hong Kong, Italy, Moldova and more
  5. Feb 9, 2024Phase 1 study in Lupus Erythematosus, SystemicArtiva Biotherapeutics · NCT06265220 · 51 enrolled · United States
  6. Feb 27, 2025Alphyn Biologics's first study: phase 2 study in Dermatitis, AtopicNew to Alphyn BiologicsAlphyn Biologics · NCT06855745 · 72 planned · Australia

Ahead

  1. Aug 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicArtiva Biotherapeutics · NCT06265220

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06855745Dermatitis, Atopic · Australia2RecruitingAlphyn BiologicsOct 30, 202572
NCT06265220Lupus Erythematosus, Systemic · United States1Active, not recruitingArtiva BiotherapeuticsAug 202751
NCT05960240Hepatitis B, Chronic · Hong Kong, Italy, Moldova and more1CompletedArbutus BiopharmaDec 4, 2025128
NCT05883449Recurrence · United States2TerminatedAffimedNov 7, 202425
NCT04673617Lymphoma, Non-Hodgkin · United States2CompletedArtiva BiotherapeuticsOct 6, 202545
NCT03592121Sexual Dysfunction, Physiological · United StatesEarly 1CompletedApplied BiologyOct 12, 20193

How it is read

Names in the registry

  • “AB-101”, 5 entries
  • “zabalafin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.